Thomson Pharma Consortium - Member Deal
BioMelbourne Network / Thomson Pharma Consortium
Introduction
Following the successful inaugural launch of the 2006 BioMelbourne / Thomson Pharma consortium initiative, we are delighted to offer new members the opportunity to join the consortium in 2008.
By means of background, BioMelbourne Network members have identified Research and Competitive Intelligence information as one of the 3 key resources required for operational effectiveness in a recent research conducted by the Network. Scientific solutions from Thomson Reuters can effectively serve this need.
The purpose of this consortium is to provide BioMelbourne Network members with access to the world class Thomson Pharma database at a very attractive, member-only discounted price.
BioMelbourne Member Discount: Please refer to the contact details below to contact Thomson Reuters. You MUST quote your membership number |
Thomson Pharma® is a comprehensive global pharmaceutical information solution that covers the entire drug discovery and development pipeline. Its competitive intelligence and strategic data can justify and speed your decision-making, facilitate more focused collaboration, and encourage innovation.
This premium content has been enhanced with powerful search tools and integrated into a single solution that professionals working at all stages of drug development can personalize to suit their needs. To find out more about Thomson Pharma®, please visit http://www.thomsonscientific.com/thomsonpharma/aboutpharma/ataglance/
VIEW a Thomson Pharma® training demo. Click here
FREE Sign up HERE for our newsletter, bulletins, updates and exclusive publication.
Now, and every quarter, Thomson Reuters takes the pulse of the industry with this lively free review of the latest phase changes in the pharmaceutical pipeline.
In The Ones To Watch you'll get expert insight into the five most promising drugs:
Why not subscribe to receive the latest edition of The Ones to Watch and get future editions delivered direct to your desktop, every quarter? Subscription is completely free and without obligation Register here
The latest edition is available now, covering the most promising drugs reaching the market and moving between clinical trials. Download your copy here
How Thomson Pharma supports Fusion Life Sciences every step of the way (to create link to PDF Fact Sheet)
Customer testimonial –
What Existing Clients think of Thomson Pharma
“I’ve been impressed with Thomson Pharma from the very beginning,” said Tim Grogan, co-founder of Fusion Life Sciences. “In our industry, we must remain competitive with ready access to detailed, diverse and up-to-date information about commercial and scientific opportunities. Thomson Pharma is what enables Fusion to take advantage of these opportunities and, in my opinion, much earlier than we would have otherwise.”
Tim Grogan, Executive Director, Fusion Life Sciences, Melbourne, Australia
Click HERE to read Tim Grogans’ full case study & testimonial
In addition, please indicate below whether you are interested in learning more about Thomson Reuter’s additional information portlets, details of which are outlined below. These are not part of the core offering above but can be subscribed to separately at a reduced rate.
To learn more about Investex Company Reports available as a separate subscription through Thomson Pharma please find our more information via the contact details below
To learn more about the Entelos Target Reports available as a separate subscription through Thomson Pharma please find our more information via the contact details below
http://www.thomsonscientific.com/thomsonpharma/modules/entelos/
Thomson Reuters is the world’s leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world’s most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to www.thomsonreuters.com.
The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Our authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what’s newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success. Scientific information solutions can be found at scientific.thomsonreuters.com
To confirm your interest in joining the Thomson Pharma consortium please contact:
Australasia
Thomson Reuters
P: +61 2 8587 7565
M: +61 434 186 254
F: +61 2 8587 7987
E: bree.gallagher@thomsonreuters.com
Disclaimer: BioMelbourne Network accepts neither responsibility nor liability for any errors and or omissions contained in the communication material or products and services in this or any other promotional offer.